ameera-3: amcenestrant does not improve pfs in er /her2- breast cancer
Published 1 year ago • 62 plays • Length 2:46Download video MP4
Download video MP3
Similar videos
-
1:51
ameera-3: serd for er her2- breast cancer
-
1:25
ameera-5: amcenestrant palbociclib for previously untreated er /her2- advanced breast cancer
-
4:40
ameera-1 updates: amcenestrant plus palbociclib for patients with er /her2– advanced breast cancer
-
2:35
ameera-6: amcenestrant, a novel serd, in hr breast cancer
-
0:52
patient eligibility in the ameera-6 trial of amcenestrant
-
1:17
key trial updates in serds in er /her2- breast cancer from sabcs 2022
-
1:00
utilizing neoadjuvant immunotherapies in patients with er , her2- primary breast cancer
-
4:06
serena-2: camizestrant vs fulvestrant in post-menopausal women with advanced er /her- breast cancer
-
0:52
first-line camizestrant for er /her2- advanced breast cancer
-
1:20
updated results of destiny-breast03: t-dxd vs t-dm1 in metastatic her2 breast cancer
-
1:27
emerald: elacestrant vs physicians choice in er /her2- breast cancer
-
3:01
assessing elacestrant in ctdna-positive patients with er breast cancer
-
1:00
the clinical significance of serum anti-müllerian hormone (amh) testing in breast cancer
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
4:53
comparing therapy benefit from initially her2 positive or negative metastatic breast cancer patients
-
3:30
final results from pallas: adjuvant palbociclib in hr /her2- early breast cancer
-
1:26
monarche: investigating adjuvant abemacicilib for high-risk hr breast cancer
-
2:03
emerald: elacestrant vs. soc for patients with er her2- metastatic breast cancer
-
1:00
therapeutic strategies to maximize sensitivity to endocrine therapy in breast cancer